Intravenous immunoglobulin for the treatment of childhood encephalitis
Encephalitis is a syndrome of neurological dysfunction due to inflammation of the brain parenchyma, caused by an infection or an exaggerated host immune response, or both. Attenuation of brain inflammation through modulation of the immune response could improve patient outcomes. Biological agents su...
Κύριοι συγγραφείς: | Iro, M, Martin, N, Absoud, M, Pollard, A |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Cochrane Collaboration
2017
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
ανά: Hill, M, κ.ά.
Έκδοση: (2023) -
Childhood encephalitis in the United Kingdom - epidemiology, trends in hospital admissions and the role of intravenous immunoglobulin
ανά: Iro, M
Έκδοση: (2018) -
Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
ανά: Iro, MA, κ.ά.
Έκδοση: (2024) -
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial
ανά: Simon Nadel, κ.ά.
Έκδοση: (2023-11-01) -
Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT
ανά: Mildred A Iro, κ.ά.
Έκδοση: (2024-04-01)